Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide (P6.372)

Timothy Spelman; Tomáš Kalinčík; Maria Trojana; François Grand’Maison; Guillermo Izquierdo; Eva Havrdová; Dana Horáková; Alessandra Lugaresi; Pierre Duquette; Pierre Grammond; Raymond Hupperts; Jeannette Lechner‐Scott; Franco Granella; Thor Petersen; Murat Terzi; Eugenio Pucci; Patrizia Sola; Vincent Van Pesch; Gerardo Iuliano; Cavit Boz; Roberto Bergamaschi; Mark Slee; Helmut Butzkueven

doi:10.1212/wnl.88.16_supplement.p6.372

Abstract

Compare time to first relapse (TTFR), annualized relapse rate (ARR), and discontinuation outcomes in patients initiating dimethyl fumarate (DMF) pair-wise versus a propensity-matched cohort of fingolimod (FTY), teriflunomide (TERI), interferons (IFN), or glatiramer acetate (GA).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Spelman et al. (2017) studied this question.

synapsesocial.com/papers/6ac708fa4e71bb5f03fae869 https://doi.org/10.1212/wnl.88.16_supplement.p6.372

View at Publisher

Ask AI

Bookmark

Share

Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide (P6.372)

Abstract

Discussion

Cite This Study

Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide (P6.372)

Abstract

Discussion

Cite This Study

Keep reading

Keep reading